NCT00961857View on ClinicalTrials.gov

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2005

Primary Completion Date

December 1, 2005

Study Completion Date

January 1, 2006

Conditions

Type 2 Diabetes

Interventions

DRUG

sitagliptin phosphate (+) metformin hydrochloride

place holder - do not post

DRUG

Comparator: metformin 500 mg

A single dose of metformin 500 mg tablets

DRUG

Comparator: sitagliptin

A single 50 mg tablet of sitagliptin

DRUG

Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet

A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet

DRUG

Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet

A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet

DRUG

Comparator: metformin 1000 mg

A single dose of metformin 1000 mg tablets

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00961857 - A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048) | Biotech Hunter | Biotech Hunter